ALKBH5 Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited population of human embryonic kidney HEK293T cells carrying targeted disruption of the ALKBH5 gene. This polyclonal knockout model provides a loss-of-function system without single-cell cloning, maintaining population diversity while achieving broad ALKBH5 ablation. The cells are supplied after antibiotic selection and are ready for use in diverse experimental assays to study ALKBH5-mediated processes.
The HEK293T host cell line, derived from HEK293 by stable integration of the SV40 large T antigen, is a widely employed human embryonic kidney line. Expression of the SV40 large T antigen enables high-copy episomal replication of plasmids containing the SV40 origin, making the line ideal for transient protein expression, viral vector production, and CRISPR/Cas9 genome editing. HEK293T cells exhibit robust adherent growth and are highly amenable to genetic manipulation and phenotypic screening, offering a versatile platform for studying ALKBH5 function.
ALKBH5 is an N6-methyladenosine (m6A) eraser that demethylates mRNA, opposing the METTL3/METTL14 writer complex. By removing m6A, ALKBH5 stabilizes transcripts and promotes translation, particularly affecting proliferation and stemness genes. Transcription is induced by HIF-1?? under hypoxia and by MYC and PI3K/AKT signaling. Downstream, ALKBH5 activity elevates expression of FOXM1, NANOG, KLF4, SOX2, MYC, and CCND1. The m6A readers YTHDF1 and YTHDF2 recognize methylated mRNA, influencing decay and translation; ALKBH5-mediated demethylation counteracts these reader functions, fine-tuning target mRNA turnover and protein output.
In the HEK293T background, ALKBH5 knockout allows dissection of m6A-dependent gene regulation in a non-tumorigenic, easily transfectable line. The SV40-immortalized status provides a baseline for evaluating ALKBH5 contributions to growth signaling and hypoxia responses without interference from oncogenic transformation. This model is particularly useful for examining the HIF-1???CALKBH5?CFOXM1 axis and for quantifying m6A changes on specific transcripts upon ALKBH5 loss. The cell line??s receptivity to plasmid transfection also facilitates rescue experiments to validate target-specific effects.
These polyclonal knockout cells support epitranscriptomic research, including global m6A analysis by dot blot, transcript-specific m6A assessment by RIP-qPCR, and mRNA stability measurement with actinomycin D chase assays. Functional assays for proliferation, migration, and invasion can be paired with RT-qPCR and western blotting to monitor downstream effectors such as FOXM1 and MYC. The model serves in drug target validation, enabling inhibitor screening in a human m6A pathway context. Hypoxia response studies can be conducted by exposing cells to low oxygen and measuring HIF-1??-dependent outputs. For further details, technical assistance, or custom orders, please contact Ascent Research.
